Domaines d'activité: Corporate / M&A

Letizia Schlegel is an attorney in the Corporate/M&A team of Walder Wyss. Her preferred areas of practice include domestic and cross-border mergers and acquisitions, corporate and commercial law as well as general contract law.

Letizia Schlegel studied law at the University of Zurich (BLaw 2016, MLaw 2018) and King's College London (LL.M. 2018). Before starting her career as an attorney, Letizia Schlegel worked as a trainee lawyer at Walder Wyss and as a law clerk in a district court in the Canton of St. Gallen. She was admitted to the bar in 2021.

Letizia Schlegel practices in both German and English. She also speaks Italian and French and has a basic knowledge of Spanish. She is registered with the Zurich Bar Registry and admitted to practice in all Switzerland.

Cultivated Biosciences closes USD 5 million Seed Financing Round

Hanseatic Power Service acquires BW Service Ltd

Walder Wyss berät LEND bei Series C Finanzierungsrunde

Sir Mary joins MYTY Group

deskbird closes USD 13 million Series A financing round

Walder Wyss advised Farmy AG on CHF 10.5m Financing Round

PENTAG Informatik AG joins collana IT group

Nexoya Series A Financing Round

Fundamenta Group acquires Belvédère Asset Management

Sale of «Nagel Group»

Walder Wyss advises Farmy on crowdfunding financing round

Baloise and UBS take over majority in homeowner platform Houzy

BCG acquires Quantis

Helbing Lichtenhahn invests in Neur.on

monami joins MYTY Group

Walder Wyss advised Planted Foods AG on CHF 70m Series B Financing Round

Ufenau Capital Partners acquires a majority stake in Dr. Niedermaier Pharma Group

Hotel Saratz Pontresina has new owner

GarLa Group acquires Enz Group AG

Teylor AG announces CHF 6.5 million Series A2 Financing Round

Avaloq acquires Derivative Partners, a Zurich-based Service Specialist for Structured Products

La société Hesse & Partner SA, qui appartient à Arthur J. Gallagher & Co. (NYSRE: AJG), reprend Verbag Versicherungsberatungs-AG

DigiCert acquiert QuoVadis

Tour de financement de série E pour $77 mio pour SOPHiA GENETICS